Mesa Laboratories, Inc. announced that it has entered into separate, privately negotiated purchase agreements with a limited number of holders of its outstanding 2025 Notes at the gross proceeds of $71,250,000 on April 5, 2024. The principal amount of the transaction is $75,000,000. The notes bear 1.375% Convertible Notes due 2025.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
118.6 USD | +0.41% | +4.76% | +13.20% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.20% | 640M | |
-4.98% | 182B | |
+2.84% | 112B | |
-2.68% | 68.58B | |
+4.53% | 51.58B | |
+8.00% | 44.24B | |
+9.65% | 43.65B | |
+25.30% | 32.46B | |
-0.17% | 25.61B | |
+21.57% | 25.99B |
- Stock Market
- Equities
- MLAB Stock
- News Mesa Laboratories, Inc.
- Mesa Laboratories, Inc. announced that it expects to receive $71.25 million in funding